Brokerages Set Senseonics Holdings, Inc. (NYSE:SENS) Target Price at $22.70

Shares of Senseonics Holdings, Inc. (NYSE:SENS) have been given an average recommendation of “Buy” by the six research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $22.70.

Several analysts have recently issued reports on the company. TD Cowen decreased their price target on Senseonics from $25.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. HC Wainwright upped their target price on Senseonics to $18.50 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Barclays reiterated an “overweight” rating and set a $31.00 price target (up previously from $1.50) on shares of Senseonics in a report on Wednesday, November 5th. Lake Street Capital upgraded shares of Senseonics to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, Stifel Nicolaus began coverage on shares of Senseonics in a research note on Tuesday, October 21st. They issued a “hold” rating and a $9.00 target price on the stock.

Insiders Place Their Bets

In related news, Director Douglas A. Roeder bought 15,000 shares of Senseonics stock in a transaction that occurred on Friday, November 7th. The stock was acquired at an average price of $5.83 per share, for a total transaction of $87,450.00. Following the completion of the purchase, the director owned 99,727 shares in the company, valued at approximately $581,408.41. This represents a 17.70% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Frederick T. Sullivan purchased 5,415 shares of the stock in a transaction on Friday, November 7th. The stock was acquired at an average cost of $5.88 per share, for a total transaction of $31,840.20. Following the acquisition, the chief financial officer directly owned 157,028 shares in the company, valued at approximately $923,324.64. This trade represents a 3.57% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 3.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SENS. Elite Life Management LLC acquired a new position in Senseonics in the second quarter valued at about $36,000. Cambridge Investment Research Advisors Inc. raised its position in shares of Senseonics by 679.9% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 289,919 shares of the company’s stock worth $190,000 after purchasing an additional 252,745 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Senseonics by 4.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,502,326 shares of the company’s stock valued at $2,298,000 after purchasing an additional 162,628 shares in the last quarter. Informed Momentum Co LLC bought a new position in shares of Senseonics during the 1st quarter valued at about $559,000. Finally, Keynote Financial Services LLC grew its position in shares of Senseonics by 1,120.2% in the 2nd quarter. Keynote Financial Services LLC now owns 208,285 shares of the company’s stock valued at $99,000 after purchasing an additional 191,215 shares during the period. Institutional investors own 12.36% of the company’s stock.

Senseonics Stock Performance

Shares of NYSE SENS opened at $6.59 on Monday. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. Senseonics has a one year low of $5.00 and a one year high of $28.00. The business’s 50-day moving average price is $8.27 and its two-hundred day moving average price is $9.76. The company has a market capitalization of $269.25 million, a P/E ratio of -50.69 and a beta of 0.79.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.